New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 12, 2012
Jim Cramer said, "2012 is no longer about global economic crisis, it's about buying stock in the companies you love." Cramer said he's no longer sweating the details of every story that hits the news wires. Because the big-money players, those who would sell on every bit of negative news, are simply no longer a part of this market. They have been replaced by good old-fashioned individual investors. When companies break up, investors win, Cramer reminded viewers, as he highlighted yet another corporate breakup story, Sara Lee (SLE). He said that shares of Sara Lee should follow in the footsteps of Beam (BEAM) and Covidien (COV), two other breakup stocks, which headed markedly higher. Sara Lee is offering a $3-a-share special dividend to shareholders when the breakup occurs. Additionally, recent analysis of Sara Lee's various components values the stock 22% higher than where it trades today. Sara Lee plans to update shareholders on its progress at an investors meeting on June 5. Investing in Sara Lee will be a slow climb, said Cramer, which is why he would use recent weakness in the stock to get in at attractive prices. Continuing with his week-long series of great American growth stocks, Cramer turned the spotlight onto Allergan (AGN). It is not only a health care company that treats eye problems and migraines, but it is also a leader in medical aesthetics, including Botox and great implants. Cramer said that Allergan has multiple years of growth ahead of it. Its end markets are huge. Also, Allergan is highly competitive in every arena in which it enters and the company pays a tiny dividend. Shares trade for just 19x earnings and the company has a 14% long-term growth rate. Giving investors another great American growth stock, Cramer also highlighted Celgene (CELG), another stock just off its 52-week high. Celgene has one of the fastest growth rates in its sector, said Cramer, and also huge market potential as a host of new products and new applications for existing products are chugging toward FDA approval. Internationally, the company is a powerhouse. Cramer said that while Celgene is unlikely to offer a dividend anytime soon, the company has done a few well-timed stock buybacks to reward shareholders. Celgene sports a rock-solid balance sheet. Celgene trades at just 13.8x next year's earnings, despite the company's 24% growth rate. NO HUDDLE OFFENSE: Cramer said that the tailwinds are all lining up for a great quarter at Home Depot (HD), and he would be a buyer of the stock, even up near its 52-week high. Case-in-point: Tractor Supply (TSCO) announced sales that are double what analysts are expecting and Titan Machinery (TITN) pre-announced strong earnings, followed by Sherwin-Williams (SHW) announcing sales up by 20%. LIGHTNING ROUND: (Bullish) STO; ESRX; GLD; KORS; WPRT; DRI; CMG; RNDY. (Bearish) AUQ; P; CHK. Reference Link
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 >>
November 16, 2015
07:50 EDTPUBS to hold a conference
Subscribe for More Information
06:33 EDTAGNPfizer, Allergan deal brings focus on U.S. tax-inversion deals, Reuters says
Pfizer's (PFE) takeover bid for Allergan (AGN) has refocused financial markets over a potential move by the U.S. Treasury Department against tax-inversion deals, Reuters reported Friday. The outlook for such a move remained unclear on Friday, the report says. Reference Link
06:18 EDTESRXDiplomat Pharmacy selloff brings 'compelling' entry point, says Leerink
Subscribe for More Information
05:31 EDTGLDSPDR Gold Trust 30-day implied volatility at 16, 52-week range 12 to 24
Subscribe for More Information
05:28 EDTHDStocks with implied volatility movement; HD ETP
Stocks with implied volatility movement; Home Depot (HD) 26, Energy Transfer Partners (ETP) 49 according to iVolatility.
November 15, 2015
18:13 EDTAGNAllergan, Pfizer targeting late November merger deal, FT says
Subscribe for More Information
November 13, 2015
14:41 EDTAGNAllergan presents EARLY analysis data at AAO meeting
Allergan announced that a post-hoc analysis of best corrected visual acuity data in diabetic macular edema patients treated with anti-vascular endothelial growth factor, or anti-VEGF, therapy suggests that long-term response in anti-VEGF treatment of DME can be assessed after three injections. Pravin Dugel, M.D., Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California and Managing Partner of Retinal Consultants of Arizona, said, "This data suggests that if treatment goals are not achieved after three injections, further expected improvement may be minimal and physicians may want to consider other treatment strategies."
11:45 EDTCMGEl Pollo LoCo sinks to 52-week low after cutting FY15 same store sales guidance
Shares of quick-service restaurant operator El Pollo LoCo (LOCO) are plunging after the company cut its fiscal 2015 same-store sales outlook and narrowed its fiscal 2015 profit view. WHAT'S NEW: Thursday night after the close, El Pollo LoCo reported third quarter adjusted earnings per share of 18c, beating analysts' consensus estimates of 15c, and revenue of $88.9M, missing the consensus of $90.4M. For the quarter, system wide SSS increased 0.6%, company owned SSS were flat, franchise SSS rose 1.1%, and adjusted EBITDA increased 9.9% to $16.6M. Chief Executive Officer Steve Sather noted that Q3 results represented the company's 17th consecutive quarter of system-wide comparable restaurant sales growth as well as pro forma net income growth of over 40%. He added that the company's new restaurant pipeline was, "strong and growing stronger." GUIDANCE: Looking ahead, El Pollo LoCo cut its FY15 system-wide comparable restaurant sales growth view to approximately 1.7% from 3%. It also lowered its outlook for openings of new company-owned restaurants to 13-15 from 16, and openings of new franchised restaurants to 5 from 8. FY15 adjusted EBTIDA guidance was cut to $64M-$66M from $65M-$67M. Due to the revised assumptions, the company narrowed its FY15 pro forma diluted EPS view to 67c-69c from 67c-71c, compared to the consensus of 68c. ANALYST REACTION: Research firm Baird downgraded El Pollo Loco to Neutral from Outperform to reflect reduced visibility, uncertain comps outlook and possible downward bias to earnings if top-line trends do not improve. Baird lowered its price target to $12 from $18 on El Pollo Loco shares. PRICE ACTION: In late morning trading, El Pollo Loco fell $1.30, or about 11.25%, to $10.22 on nearly four times its average daily trading volume. Earlier in the session, the stock hit a fresh 52-week low of $9.58. Over the past 12 months, the stock is down approximately 70%. OTHERS TO WATCH: Other quick-service restaurants include Fiesta Restaurant (FRGI), down 2.5%, Chipotle Mexican Grill (CMG), down 2.7%, Del Taco (TACO), down 2.15%, Popeyes Louisiana Kitchen (PLKI), down 1.3%, and Bojangles (BOJA), down fractionally.
11:33 EDTCMGStocks with call strike movement; CBS CMG
Subscribe for More Information
11:12 EDTAGNPiper sees Pfizer profiting from Allergan deal, worth $50/share even without one
An acquisition of Allergan (AGN) by Pfizer (PFE) would increase the latter company's profits in 2016-2017 and lift its earnings by a large amount by 2019, wrote research firm Piper Jaffray in a note to investors today. WHAT'S NEW: By 2019, an acquisition of Allergan would increase Pfizer's earnings per share by 13%-16%, estimated Piper analyst Richard Purkiss. The deal would be profitable for Pfizer as early as 2016, the analyst believes. Excluding any acquisition, Pfizer is worth over $50 per share, well above analysts' average price target of $40, Purkiss believes. He kept a $52 price target and Overweight rating on Pfizer. WHAT'S NOTABLE: Yesterday dealReporter, noting that an acquisition of Allergan by Pfizer would be "a giant inversion deal," asserted that the U.S. Treasury could look to take steps to limit or discourage those types of transactions. On November 6, research firm Bernstein said that Allergan's strong results, coupled with the weakness of drug stocks, could cause Allergan to be reluctant to sell itself to Pfizer in the near-term. As a result, the firm thinks that the odds of a deal getting done may be lower than many believe. It kept a $385 price target and Outperform rating on Allergan. PRICE ACTION: In late morning trading, Pfizer rose fractionally to $33.47 and Allergan added 1.3% to $303.87.
11:02 EDTCELGCelgene calls active on renewed takeover chatter
Celgene November weekly 111 and 112 calls are active on total call volume of 9K contracts (3K puts) on renewed takeover chatter. November weekly call option implied volatility is at 82, November is at 42, December is at 35; compared to its 52-week range of 23 to 54. Active call volume suggests traders taking positions for large price movement.
10:58 EDTCELGRumor: Celgene moves up on renewed takeover chatter
Subscribe for More Information
10:49 EDTCMGChipotle breaks back below $600 on lower consumer brand perception
Subscribe for More Information
10:49 EDTAGNMylan jumps, Perrigo plunges after hostile takeover bid fails
Shares of Mylan (MYL) jumped after the company's offer to acquire Perrigo (PRGO) failed. Perrigo shares fell after the news. WHAT'S NEW: Mylan's approximately $26B hostile takeover offer for Perrigo officially fell through Friday morning, ending a seven-month ordeal between the two companies. Mylan said that only about 40% of Perrigo's shares were tendered by the company's stockholders, falling short of the 50% required for an acquisition, forcing the offer to lapse after failing to meet its goal by the established deadline. In response to the news, Perrigo Chief Executive Officer Joseph Papa said he was "delighted" that his company's shareholders rejected the offer. "We have said all along that this offer from Mylan was a bad deal for our shareholders, as it significantly undervalued our durable business model and industry-leading future growth prospects," Papa said. Perrigo added that it will immediately commence its previously announced $2B share buyback and that it intends to complete $500M of the planned repurchase by the end of the year. WHAT'S NOTABLE: On July 27, Teva (TEVA) withdrew a takeover offer for Mylan amid Mylan's talks with Perrigo. The Israeli pharmaceutical company opted instead to purchase Allergan's (AGN) generics business. Commenting on its failure to buy Perrigo, Mylan Executive Chairman Robert Coury said in a statement that while the company viewed Perrigo as a "unique and exciting company," it was not required for the future success of the company. Coury said, "We are well-positioned to quickly execute on the next strategic, value-enhancing opportunities for our business, some of which we have already identified." STREET RESEARCH: Citi analyst Liav Abraham upgraded Mylan to Buy and raised her price target for shares to $59 from $52, saying that an overhang has been removed since the company's hostile attempt to buy Perrigo has fallen through. Abraham argued that a combination of the two companies would have been both destructive to both earnings and value for Mylan and that the failed bid will increase management's optionality to pursue other value-enhancing opportunities and enable investors to focus on the company's base business. In addition, RBC Capital Markets analyst Randall Stanicky confirmed a Sector Perform rating for both Mylan and Perrigo with price targets of $60 and $176, respectively. Stanicky said he expects Mylan's stock to gain 10%-15% towards $50 as a result of the news, while Perrigo will probably see a pull-back into the low $140s. The analyst added that the removal of the Mylan bid will drive initial weakness for Perrigo's shares but that the stock can settle close to its current levels. PRICE ACTION: In morning trading, Mylan rallied 12.5% to $48.60 and Perrigo fell 6.92% to $145.72. OTHERS TO WATCH: Teva shares trading in New York increased 0.26%, Allergan was up 0.66%, and Endo (ENDP), with which Reuters reported Perrigo held unsuccessful takeover talks, gained 5.56%.
08:22 EDTAGNAmerican Academy of Ophthalmology to hold annual meeting
AAO 2015 is being held in Las Vegas, Nevada on November 13-17 with webcasted presentations to begin on November 13 at 11:50 am. Webcast Link
08:05 EDTRNDYRoundy's buyout shows Fresh Market undervalued, sayst Jefferies
Jefferies analyst Mark Wiltamuth says Kroger's (KR) acquisition of Roundy's (RNDY) reaffirms his view that The Fresh Market (TFM) is undervalued. Fresh Market shares trade at 6 times EV/EBITDA, below the 6.9 times EV/EBITDA paid by Kroger for Roundy's, and the company has a "superior" margin, free cash flow and growth profile, Wiltamuth tells investors in a research note. With a new CEO exploring strategic options, either a "buyout or a new turnaround effort are brewing" for Fresh Market, the analyst contends. He keeps a Buy rating on the stock with a $29 price target.
06:54 EDTAGNPiper sees Pfizer worth over $50/share on standalone basis
Subscribe for More Information
06:36 EDTCMGChipotle hits lowest consumer perception since 2007, CNBC reports
Subscribe for More Information
06:04 EDTSTOStatoil reports successful bids for six exploration licenses offshore Canada
Subscribe for More Information
05:15 EDTGLDSPDR Gold Trust 30-day implied volatility at 16, 52-week range 12 to 24
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use